Healthcare
Live Price
Offline$228.39
-2.48% today
1Y Change
+50.93%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Johnson & Johnson (JNJ) is a Healthcare stock with a market cap of $548.73B and listed on NYSE. The stock last traded around $228.39 and up 50.9% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +6.0%, EPS growth of +88.9%, a dividend yield of 2.3%. What stands out right now is revenue +6.0%, EPS +88.9%, free cash flow -0.7% with operating margin 26.9% and ROIC 13.6%. The dividend is present but secondary, with a yield around 2.3%. Valuation sits in the middle of the pack at P/E 26.5 and price/sales 5.7. Stock Foundry combines JNJ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
JNJ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
JNJ Max Drawdown
-10.96%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for JNJ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$78.7B
-1.6% YoY
FY Net Income
$20.9B
+16.4% YoY
Free Cash Flow
$19.8B
+15.0% YoY
Revenue Growth
+6.0%
EPS Growth
+88.9%
Gross Margin
69.1%
Net Margin
21.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 94.2B | 88.8B | 85.2B | 80.0B | 78.7B |
| Gross Profit | 68.6B | 61.4B | 58.6B | 55.4B | 55.3B |
| Operating Income | 25.6B | 22.1B | 23.4B | 21.0B | 20.9B |
| EBITDA | 39.9B | 24.8B | 23.3B | 26.6B | 26.8B |
| Net Income | 26.8B | 14.1B | 35.2B | 17.9B | 20.9B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | 19.7B | 24.1B | 21.9B | 12.9B | 14.5B |
| Total Assets | 199.2B | 180.1B | 167.6B | 187.4B | 182.0B |
| Total Liabilities | 117.7B | 108.6B | 98.8B | 110.6B | 108.0B |
| Shareholder Equity | 81.5B | 71.5B | 68.8B | 76.8B | 74.0B |
| Total Debt | 47.9B | 36.6B | 29.3B | 39.6B | 33.8B |
| Net Debt | 28.2B | 12.5B | 7.5B | 26.8B | 19.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
23.4B
+10.5% YoY
Capital Expenditures
3.7B
+8.9% YoY
Free Cash Flow
19.8B
+15.0% YoY
Key ratios
Gross Margin
69.1%
Operating Margin
26.9%
Net Margin
21.8%
ROE
26.3%
Debt / Equity
0.22x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.